

MAILING CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington D.C. 20231 on

Jan 10, 2001  
Date

Kay Bulen  
Signature

Kay Bulen  
(print name)

GP/1642WD  
Box/Seq  
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 23 2001

Applicants: Doherty et al.

Filing Date: 31 July 2000

Serial No.: 09/630,155

For: HER-2 BINDING ANTAGONISTS

Art Unit: 1642

Examiner: J. Hunt

Docket: 49321-10

Date: 10 January 2001

Box SEQUENCE

Assistant Commissioner for Patents  
Washington, DC 20231



TECH CENTER 1600/2900  
RECEIVED

JAN 19

TECH CENTER 1600/2900

**RESPONSE TO NOTICE TO COMPLY UNDER C.F.R. 1.821**

Sir or Madam:

Applicant's submit the attached Preliminary Amendment, Associate Power of Attorney, Sequence Listing (under C.F.R. 1.821(c) and (e)) and Statement (under C.F.R. 1.821(f)), in response to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES, attached to the Office Communication, dated 12 December 2000. No new matter has been added.

**REMARKS**

Applicant's, while including a sequence listing in the above-identified divisional application (i.e., at pages 25-29), failed to submit a separate sequence listing. Accordingly, applicants now submit the appropriate sequence listing in paper (C.F.R. 1.821(c)) and computer-readable form (C.F.R. 1.821(e)), along with applicant's statement under (C.F.R. 1.821(f)). Minor corrections to the Sequence Listing, as originally disclosed in the specification, have been made to bring the sequence listing into conformity with the requirements of C.F.R. 1.821-1.825. The presently-submitted Sequence Listing conforms with that of the underlying parent application (Serial No. 09/234,208). No new matter has been added.